IL15 and cancer: Human ILC3s treated with IL-15 and IL-12 initiate the expression of NK cell cytotoxicity markers (Eomes, CD94, CD56 NKG2A, and NKG2C), suggesting a beneficial role for ILC3-NK plasticity in cancer (155, 156).